Press Releases

November 23, 2020

SQZ Biotech to Present at Evercore ISI Virtual HealthCONx Conference

November 12, 2020

SQZ Biotech to Present at November Virtual Investor Conferences

November 10, 2020

SQZ Biotech Presents Preclinical Data for SQZ APC and AAC Cellular Vaccine Platforms at SITC 2020, Including First-Time SQZ APC Combination Preclinical Data

October 30, 2020

SQZ Biotech Announces Pricing of Initial Public Offering

October 23, 2020

SQZ Biotech Strengthens Board of Directors and Appoints New Chief Business Officer

July 20, 2020

SQZ Biotech Appoints Paul Bolno, MD to Board of Directors and Kai Wucherpfennig, MD, PhD to Scientific Advisory Board

May 26, 2020

SQZ Biotech to Participate in June Investor Conferences

May 18, 2020

SQZ Biotech Closes $65 Million Series D Financing

May 11, 2020

SQZ Biotech to Present at UBS Virtual Global Healthcare Conference

January 30, 2020

SQZ Biotech Announces First Patient Dosed in Phase 1 Trial of SQZ-PBMC-HPV for HPV+ Tumors

November 12, 2019

SQZ Biotech to Present at Upcoming Investor Conferences in November & December

November 7, 2019

SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies

November 5, 2019

SQZ Biotech to Present First Time Data Demonstrating Potential of Company’s Second Novel Cell Therapy Approach in Oncology – Activating Antigen Carriers (AACs)

October 31, 2019

SQZ Biotech to Present New Data at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

October 22, 2019

SQZ Biotech Announces Clearance of US IND Application for First Clinical Trial

September 17, 2019

SQZ Biotech Appoints Legal Life Sciences Expert, Lawrence Knopf, as General Counsel

August 7, 2019

SQZ Biotech Announces Appointment of Experienced Pharmaceutical Executive Teri Loxam as Chief Financial Officer

May 29, 2019

SQZ Biotech Strengthens Board of Directors with Appointment of Leading Cell Therapy Expert and Biotech Veteran

May 14, 2019

SQZ Biotech to Present at Investor Conferences in May & June

April 25, 2019

SQZ Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 22nd Annual Meeting

March 28, 2019

SQZ Biotech to Present at the Jefferies Immuno-Oncology Cell Therapy Summit

March 5, 2019

SQZ Biotech to Present at Investor Conferences in March

February 28, 2019

SQZ Biotech to Present at the American Association for Cancer Research (AACR) 2019 Annual Meeting

January 3, 2019

SQZ Biotech Strengthens Leadership Team with Appointment of Chief Medical Officer

November 9, 2018

SQZ Biotech to Present at Investor Conferences in November

November 1, 2018

SQZ Biotech Announces PNAS Publication Demonstrating Significant Advantages of Its Cell Squeezing Technology for the Development of Cell-Based Therapeutics

October 15, 2018

SQZ Biotech Expands Cell Therapy Partnership with Roche to Develop Antigen Presenting Cells for Immune-Oncology

September 27, 2018

SQZ Biotech Announces Key Executive and Board of Directors Appointments

August 8, 2018

SQZ Completes Oversubscribed Series C

May 14, 2018

SQZ Biotech CEO to Participate in BIO International Panel and to Present at Investor Conferences in Second Quarter 2018

February 5, 2018

SQZ Biotech to Present at Investor Conferences in First Quarter 2018

December 5, 2017

SQZ Biotech Receives Investment from JDRF T1D Fund

June 14, 2017

SQZ Biotech Named a 2017 Technology Pioneer and Gives Corporate Update

December 1, 2016

SQZ Biotech Announces Additional $8 Million in Series B Funding Bringing Total Financing Round to $24 Million

September 30, 2016

SQZ Biotech Announces $16 Million Series B Funding Round Led by Nanodimension and Polaris Partners

December 7, 2015

SQZ Biotech Announces Partnership to Fight Cancer with Novel Cell Engineering Technology

June 23, 2015

SQZ Biotech Raises $5 Million Series A Round Led By Polaris Partners

November 18, 2014

SQZ Biotech’s CellSqueeze Featured as a Top 10 Innovation in Scientific American’s World Changing Ideas 2014

October 30, 2014

SQZ Biotech Launches SQZ Cell Therapy Platform and Is Awarded $100,000 Grand Prize from MassChallenge and over $200,000 from Boeing and the Center for the Advancement of Science in Space (CASIS)